Citius Unveils Promising LYMPHIR Data at EORTC Conference
A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...
Continue Reading